The Lancet Haematology
The Lancet Haematology
Atsushi Sakamoto,Toru Uchiyama,Kazuki Tanimura et al.
Atsushi Sakamoto et al.
Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implications [0.03%]
von Willebrand因子和von Willebrand病在衰老中的作用：机制、表型演变及临床意义
Omid Seidizadeh,Ferdows Atiq,Nathan T Connell et al.
Omid Seidizadeh et al.
The global population is ageing and this demographic shift has profound effects on haemostasis, notably a progressive tilt towards a hypercoagulable state. A major age-associated change in haemostasis is the increase in von Willebrand facto...
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial [0.03%]
Belantamab马莫度汀、泊马度胺和地塞米松与硼替佐米、泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者后的患者报告结局：DREAMM-8 3期开放标签随机对照试验
Meletios A Dimopoulos,Meral Beksac,Ludek Pour et al.
Meletios A Dimopoulos et al.
Background: In the DREAMM-8 trial, belantamab mafodotin, pomalidomide, and dexamethasone demonstrated a statistically significant reduction in the risk of progression or death compared with bortezomib, pomalidomide, and d...
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study [0.03%]
低耐受羟基脲或对羟基脲反应不佳的原发性血小板增多症患者的alfa-2b罗贝戈干扰素治疗：一项多中心、开放标签、随机对照、III期研究（SURPASS ET）
Ruben Mesa,Harinder Gill,Lei Zhang et al.
Ruben Mesa et al.
Background: The initial therapy for high-risk essential thrombocythaemia is usually hydroxyurea, but about a third of patients develop intolerance or resistance. A standard second-line agent has been anagrelide. Ropeginte...
Perspectives of potential haematopoietic stem-cell donors on education TikToks [0.03%]
潜在造血干细胞捐献者对教育类TikTok视频的看法
Yin Cathy Jian,Brady Park,Shangari Vijenthira et al.
Yin Cathy Jian et al.
Incorporating national disease burden in GBD estimates of haemoglobinopathies in Italy [0.03%]
意大利GBD中血红蛋白病国家疾病负担的估计
Barbara Gianesin,Frédéric B Piel,Lucia de Franceschi et al.
Barbara Gianesin et al.
Can ropeginterferon SURPASS resistance in essential thrombocythaemia? [0.03%]
绳子干扰素能否克服原发性血小板增多症的耐药性？
Marko Lucijanic,Ivan Krecak
Marko Lucijanic
Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia [0.03%]
细胞因子工程CAR-T细胞治疗复发或难治B细胞急性淋巴细胞白血病
Rawan G Faramand,Lori Muffly
Rawan G Faramand